119 related articles for article (PubMed ID: 28913867)
1. Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab.
Kimura K; Kobayashi D; Hatoyama S; Yamamoto M; Takayanagi R; Yamada Y
APMIS; 2017 Dec; 125(12):1102-1107. PubMed ID: 28913867
[TBL] [Abstract][Full Text] [Related]
2. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
[TBL] [Abstract][Full Text] [Related]
3. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Iwasaki M; Shimada N; Kasuga Y; Yokoyama S; Onuma H; Nishimura H; Kusama R; Hamada GS; Nishimoto IN; Iyeyasu H; Motola J; Laginha FM; Anzai R; Tsugane S
Breast Cancer Res Treat; 2011 Apr; 126(2):497-505. PubMed ID: 20697800
[TBL] [Abstract][Full Text] [Related]
4. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
[TBL] [Abstract][Full Text] [Related]
5. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
[TBL] [Abstract][Full Text] [Related]
7. SNPs rs4656317 and rs12071048 located within an enhancer in FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell-mediated ADCC by transcriptional regulation.
Oboshi W; Watanabe T; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Oct; 77(10):997-1003. PubMed ID: 27338556
[TBL] [Abstract][Full Text] [Related]
8. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
[TBL] [Abstract][Full Text] [Related]
9. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
10. [Effect of FCGR3A Polymorphisms on Antibody-dependent Cetuximab-mediated Cytotoxicity in A549 Cells].
Li JY; Zhu YY; Zhang GQ; Sun SJ; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):645-9. PubMed ID: 26725386
[TBL] [Abstract][Full Text] [Related]
11. Association of FcγRIIIa-158V/F with systemic lupus erythematosus in a Chinese population.
Dai M; Zhou Z; Wang X; Qian X; Huang X
Int J Rheum Dis; 2013 Dec; 16(6):685-91. PubMed ID: 24131500
[TBL] [Abstract][Full Text] [Related]
12. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
13. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity.
Moroi R; Endo K; Kinouchi Y; Shiga H; Kakuta Y; Kuroha M; Kanazawa Y; Shimodaira Y; Horiuchi T; Takahashi S; Shimosegawa T
Immunogenetics; 2013 Apr; 65(4):265-71. PubMed ID: 23358932
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
16. [Fcγ receptorIIIa polymorphism in healthy children and those with hematological malignancies].
Qu YH; Li Y; Wu YF; Fang JP; Wei J; Huang SL; Ma XX; Huang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):959-62. PubMed ID: 20723308
[TBL] [Abstract][Full Text] [Related]
17. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
18. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
[TBL] [Abstract][Full Text] [Related]
19. Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant.
Phaahla NG; Lassaunière R; Da Costa Dias B; Waja Z; Martinson NA; Tiemessen CT
Front Immunol; 2019; 10():735. PubMed ID: 31024562
[TBL] [Abstract][Full Text] [Related]
20. FcγRIIIa-158V/F polymorphism affects the performance of FcγRIIIa-related bioassay.
Aoyama M; Tada M; Ishii-Watabe A
Biochem Biophys Res Commun; 2022 Jun; 608():149-155. PubMed ID: 35398612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]